文献
J-GLOBAL ID:202002249577330067
整理番号:20A2364956
日本における遺伝性トランスチレチンアミロイドーシス患者の特性とTafamidisメグルミンの安全性の評価:全症例市販後調査の中間分析【JST・京大機械翻訳】
Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance
著者 (8件):
Ishii Tomonori
(Pfizer Pharmaceuticals KK, Tokyo, Japan)
,
Hirano Yoko
(Pfizer Pharmaceuticals KK, Tokyo, Japan)
,
Matsumoto Noriko
(Pfizer R&D Japan GK, Tokyo, Japan)
,
Takata Ami
(Pfizer R&D Japan GK, Tokyo, Japan)
,
Sekijima Yoshiki
(Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, Japan)
,
Ueda Mitsuharu
(Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan)
,
Ando Yukio
(Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan)
,
Ando Yukio
(Department of Pharmacy, Nagasaki International University, Nagasaki, Japan)
資料名:
Clinical Therapeutics
(Clinical Therapeutics)
巻:
42
号:
9
ページ:
1728-1737.e6
発行年:
2020年
JST資料番号:
A1157A
ISSN:
0149-2918
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)